revascularisation procedure) avoided at 6 months in high risk patients undergoing coronary revascularisation treated with abciximab …: 62 abciximab-treated patients and 62 patients not treated with abciximab with high risk coronary lesions were matched … variability in the data. Results: At 6 months, abciximab-treated patients experienced an approximately 40% lower rate of ischaemic …

angioplasty (PCTA). PTCA could be administered with or without abciximab (a glycoprotein IIb/IIIa receptor antagonist), stent, or … stent plus abciximab (stent+). Results: CABG/stent alone has an incremental cost of more than Lstg 115 489 per additional … CABG/ stent would be added to abciximab (CABG/stent+) its incremental cost-effectiveness ratio would be Lstg 2529 per extra …

Objective: To examine the effect of abciximab treatment on intensive care length of stay for patients undergoing … abciximab was associated with a significantly shorter length of stay in intensive care compared with not administering a GPIIb … = 4793), administration of abciximab was also associated with a significantly shorter intensive care stay (0.27 fewer days; p …

coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to … were randomised (2 : 5 ratio) to urokinase plus placebo or to urokinase plus abciximab. Economically relevant data were … more favourable for treatment with abciximab plus urokinase than for urokinase alone [9723 euros (EUR) vs EUR10 322; 2000 …

Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb … abciximab, as an adjunct to aspirin and heparin, to reduce by around one-third to one-half the incidence of ischaemic … risk, and abciximab also reduces complications in patients undergoing coronary stenting, although the drug does not appear …